ProKidney Corp. announced Dr. Bruce Culleton, EVP Clinical Development and Commercialization, to be appointed the company CEO upon Dr. Tim Bertram?s transition to an advisory role. As the Company progresses into pivotal development and commercialization, the company announce the appointment of Dr. Bruce Culleton as the Company?s CEO, effective November 15, 2023.

Dr. Culleton will also join the company board of directors. Dr. Tim Bertram will transition from his current role as director and CEO to a scientific advisory role. Dr. Culleton joined the company in July 2023 as Executive Vice President of Clinical Development and Commercialization.

Dr. Culleton has dedicated his 25-year professional career to improving the health and quality of life of patients with kidney disease. Over this time his responsibilities have included direct patient care, clinical research, product development, and executive leadership positions at Baxter Healthcare and CVS Kidney Care, a wholly owned subsidiary of CVS Health. Dr. Culleton earned a Doctor of Medicine degree from Memorial University of Newfoundland, and a Master?s Degree in Business Administration from Northwestern University, Kellogg School of Management.

He completed specialization in Internal Medicine and Nephrology through the Royal College of Physicians and Surgeons of Canada, as well as a fellowship in Clinical Epidemiology at Boston University, Framingham Heart Study.